Printer Friendly

IDEC PHARMACEUTICALS REPORTS CLINICAL PROGRESS WITH ITS PAN-B PRODUCT CANDIDATES FOR LYMPHOMA THERAPY

 SAN DIEGO, July 22 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (NASDAQ: IDPH) today announced several areas of clinical progress using its pan-B antibodies for targeted lymphoma therapy. The company's genetically engineered pan-B antibody has completed a 15-patient, single-dose, safety study at Stanford University Medical Center. Based on encouraging clinical data, preparations are now being made to begin a Phase I/II multiple-dose safety and efficacy study for the treatment of relapsed B-cell lymphoma. In addition, IDEC's radiolabeled, therapeutic pan-B antibody and its companion, radiolabeled pan-B imaging agent, have recently begun human clinical testing at Stanford. Preparations are now being made to extend the testing of all of the pan-B product candidates to three San Diego medical centers.
 As reported in a separate press release also issued today, IDEC Pharmaceuticals has discontinued development of the SPECIFID(TM) panel of 15 anti-idiotype antibodies for the treatment of lymphoma and will now focus its lymphoma program on the development of its single-antibody pan-B product candidates. Unlike SPECIFID, which targets tumors of approximately 25 percent of patients with non-Hodgkin's B-cell lymphoma, the pan-B antibodies target the CD20 cell-surface marker that is present in greater than 90 percent of lymphomas. While the presence of such a cell-surface marker does not necessarily predict efficacy, pan-B antibodies potentially address a larger patient population than SPECIFID.
 "We are enthusiastic about the prospects for the pan-B antibody candidates. Our genetically engineered pan-B antibody is designed to harness the patient's natural immune-system mechanisms to treat lymphoma by depleting malignant cells while also temporarily depleting normal B cells," said Antonio Grillo-Lopez, M.D., vice president of medical and regulatory affairs of IDEC. Preliminary animal studies showing the safety and activity of the engineered pan-B antibody for B-cell depletion in the blood and lymphatic tissues were presented by IDEC scientists at the American Society of Hematology meeting in December 1992. This study also showed that normal B cells were spontaneously regenerated from precursor cells in the bone marrow following treatment with the engineered antibody.
 IDEC Pharmaceuticals is also developing radiolabeled pan-B antibodies to target the patient's B cells by delivering radioisotopes to detect and combat lymphatic tumors. "Since radiation plays an important role today in managing lymphomas, our yttrium-conjugated pan-B antibody and companion indium-conjugated pan-B imaging agent are designed to provide targeted radiation therapy," commented Dr. Grillo- Lopez.
 IDEC Pharmaceuticals is focused on the development of targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company's most advanced product candidates include the pan-B agents, the MELIMMUNE(TM) antibodies for treatment of malignant melanoma, and a PRIMATIZED(TM) antibody for therapy of autoimmune diseases. These agents typically are designed to act through immune system mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. They also can be administered in outpatient settings, potentially helping to reduce overall treatment costs.
 IDEC Pharmaceuticals in located at 11011 Torreyana Road, San Diego, CA 92121.
 -0- 7/22/93
 /EDITOR'S NOTE: IDEC Pharmaceutical issued a second press release today entitled: "IDEC Pharmaceuticals Discontinues Development of SPECIFID(TM) Product Candidate, Redirects Lymphoma Program."/
 /CONTACT: Richard W. Krawiec, director, investor relations and corporate communications, or William H. Rastetter, president and CEO, of IDEC Pharmaceuticals, 619-550-8656/
 (IDPH)


CO: IDEC Pharmaceuticals Corporation ST: California IN: MTC SU:

EH-LS -- SD010 -- 4762 07/22/93 16:34 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 22, 1993
Words:555
Previous Article:IDEC PHARMACEUTICALS DISCONTINUES DEVELOPMENT OF SPECIFID(TM) PRODUCT CANDIDATE, REDIRECTS LYMPHOMA PROGRAM
Next Article:/C O R R E C T I O N -- WASHINGTON WATER POWER/
Topics:


Related Articles
IDEC PHARMACEUTICALS TAKES STEPS TO SPEED DEVELOPMENT OF PAN B ANTIBODIES FOR CANCER THERAPY
IDEC PHARMACEUTICALS ANNOUNCES ADVANCE AT INTERNATIONAL SCIENTIFIC CONFERENCE
IDEC PHARMACEUTICALS REPORTS INTERIM PHASE I/II CLINICAL STUDY RESULTS ON THE TREATMENT OF MALIGNANT MELANOMA
IDEC PHARMACEUTICALS DISCONTINUES DEVELOPMENT OF SPECIFID(TM) PRODUCT CANDIDATE, REDIRECTS LYMPHOMA PROGRAM
IDEC PHARMACEUTICALS(R) INITIATES LYMPHOMA TRIAL WITH ENGINEERED PAN-B ANTIBODY IN COMBINATION WITH CHEMOTHERAPY
IDEC PHARMACEUTICALS REPORTS CLINICAL DATA FOR LEAD PRODUCT AT ANNUAL MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY
IDEC TO REPORT ON LYMPHOMA TRIAL COMBINING IDEC-C2B8 WITH CHEMOTHERAPY; SYNERGISTIC ACTIVITY PROVIDES POTENTIAL FOR MORE EFFECTIVE TREATMENT
IDEC PHARMACEUTICALS COMPLETES PATIENT ACCRUAL IN IDEC-C2B8 PHASE III PIVOTAL TRIAL
IDEC PHARMACEUTICALS UPDATES LYMPHOMA TRIAL RESULTS FOR IDEC-C2B8, BOTH AS SINGLE AGENT AND IN COMBINATION WITH CHEMOTHERAPY
IDEC PHARMACEUTICALS ANNOUNCES POSITIVE PRELIMINARY RESULTS FOR PIVOTAL TRIAL OF IDEC-C2B8

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters